HT-102 not checked
Suzhou HepaThera Biotech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HT-101 given by subcutaneous injection.HT-102 given by subcutaneous injection.”In the company’s words, NCT07917910 on ClinicalTrials.gov
- Tested for
- Chronic Hepatitis B (2 trials), Chronic Hepatitis B Virus Infection
- Main trialPhase 2
- “This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extension period. The main trial phase aims to explore the efficacy of different courses of HT-101 injection combined with HT-102 injection in treating patients with chronic hepatitis B and evaluate the optimal treatment strategy. The extension period phase, based on the main trial, assesses the long-term safety and efficacy…”In the company’s words, NCT07245953 on ClinicalTrials.gov
Other drugs for Chronic Hepatitis B
- GST-HG141Fujian Akeylink Biotechnology Co., Ltd. · Phase 3
- AHB-137Ausper Biopharma Co., Ltd. · Phase 3
- ZM-H1505RShanghai Zhimeng Biopharma, Inc. · Phase 3
- TQA3605Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Tenofovir DFGilead (Kite) · Phase 3
- HT-101Suzhou HepaThera Biotech Co., Ltd. · Phase 2
Coming up3
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 24 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Oct 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Feb 2027 | A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection | |
| Phase 2Not yet recruiting | 30 Oct 2028 | A Study of HT-101 and HT-102 in Chronic Hepatitis B (CHB) | |
| Phase 1/2Active, not recruiting | 24 Aug 2027 | A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection | |
| Phase 1Completed | 12 Mar 2024 | Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients With Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026